by The tacrolimus market comprises immunosuppressant drugs that help prevent rejection of transplanted organs. Tacrolimus acts by inhibiting the body’s immune system from attacking and destroying the transplanted organ. It is a calcineurin inhibitor used for suppressing the immune system in patients who have undergone organ transplants of liver, kidney, heart, and lung. The need for organ transplantation is increasing globally due to lifestyle diseases and rise in accidents leading to organ failure. As a result, the demand for efficient post-transplant immunosuppressant drugs is growing.
The Global tacrolimus market is estimated to be valued at US$ 7822.21 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the tacrolimus market are Domtar Corporation, Medline Industries Inc., Cardinal Health, Attends Healthcare Products Inc., Kimberly-Clark Corporation, Dynarex Corporation, Tanga.com, Sarasota Medical, SCA, First Quality Enterprises Inc., Prevail, Cypress Medical Products LLC, Shield Healthcare LLC, 3M, McKesson Corporation, Ontex. Key players are focusing on expanding their geographical presence and developing more efficacious drug delivery methods for tacrolimus.
The key opportunities in the tacrolimus market include the scope for pipeline drugs with improved pharmacokinetic profiles and targeted delivery. Technological advancements pertaining to organ transplantation such as 3D bioprinting of organs can help increase the number of organ transplants conducted globally. This will further bolster the demand for post-transplant immunosuppressant drugs like tacrolimus.
Market drivers
The growing geriatric population prone to organ failures drives The Tacrolimus Market. As per WHO, the number of people aged 65 years and older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050. Moreover, the increasing prevalence of lifestyle diseases such as diabetes, hypertension, and coronary artery diseases that can damage vital organs and require transplantation also fuels market growth. Better healthcare infrastructure and availability of reimbursement programmes in developed nations have increased organ transplantation rates worldwide. This acts as a key growth propeller for the tacrolimus market.
Current challenges in the Tacrolimus Market:
The tacrolimus market is facing several challenges currently. Regulatory issues are a major challenge as various countries have different approval processes which can delay drug launches. Developing new formulations that provide better efficacy is also a challenge due to high research and development costs involved. Maintaining affordability of tacrolimus drugs is another challenge as the production costs are high. Ensuring consistent supply of raw materials required for manufacturing is also a critical challenge due to dependence on imports from select countries.
SWOT Analysis
Strength: Tacrolimus has demonstrated strong efficacy in suppressing rejection in organ transplant patients. It has become the standard of care for kidney transplant patients.
Weakness: Tacrolimus has nephrotoxic and diabetogenic side effects with long term use which can reduce quality of life. It also requires therapeutic drug monitoring to ensure safety.
Opportunity: Developing once-weekly or once monthly formulations can improve adherence for patients. New indications in other autoimmune disorders can boost growth.
Threats: Patent expiries of blockbuster brands allow generics to capture market share. Stringent regulations delay approvals of new formulations.
Geographical regions of concentration
North America dominates the global tacrolimus market currently due to high organ transplant volumes in countries like the United States. Europe is the second largest market. Both regions account for over 70% of the global market value currently.
Fastest growing region
Asia Pacific region is expected to witness the highest growth during the forecast period. Countries like China, India, Japan and South Korea are experiencing rise in kidney failure cases as well as increasing organ transplant volumes which will drive strong demand for immunosuppressants like tacrolimus in coming years. Government initiatives to boost healthcare access in many Asian countries will further support market growth.
